Secukinumab moves toward approval for psoriasis treatment

An advisory committee for the Food and Drug Administration has voted to support approval of AIN457 (secukinumab, Novartis) for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.